"Breakthrough" drugs and growth in expenditure on prescription drugs in Canada

British Medical Journal

Volumn 331, Issue 7520, 2005, Pages 815-816

  Morgan, Steven G ^a   Bassett, Kenneth L ^a   Wright, James M ^a   Evans, Robert G ^a   Barer, Morris L ^a   Caetano, Patricia A ^a   Black, Charlyn D ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL; ESOMEPRAZOLE; GENERIC DRUG; INFLIXIMAB; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ARTICLE; CANADA; COST CONTROL; DEVELOPED COUNTRY; DRUG APPROVAL; DRUG COST; HEALTH CARE COST; PATENT; PRESCRIPTION; PRIORITY JOURNAL;

BRITISH COLUMBIA; HEALTH EXPENDITURES; HUMANS; PRESCRIPTIONS, DRUG;

EID: 26644442332     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.38582.703866.AE     Document Type: Article

References (5)

1. Canadian Institute for Health Information. Drug expenditures in Canada 1981-2004. Ottawa: CIHI, 2005.
2. Patented Medicine Prices Review Board. Annual report 2003. Ottawa: PMPRB, 2004:49.
3. World Health Organization. Guidelines for ATC classification and DDD assignment 2004. 7th ed. Oslo: WHO Collaborating Centre for Drug Statistics Methodology, 2004.
4. Davis P. "Tough but fair"? The active management of the New Zealand drug benefits scheme by an independent Crown agency. Aust Health Rev 2004;28:171-81.
5. IMS. Global pharmaceutical sales fry region, 1997-2004. IMS Health, 2005.